JP2024526237A5 - - Google Patents

Info

Publication number
JP2024526237A5
JP2024526237A5 JP2023580418A JP2023580418A JP2024526237A5 JP 2024526237 A5 JP2024526237 A5 JP 2024526237A5 JP 2023580418 A JP2023580418 A JP 2023580418A JP 2023580418 A JP2023580418 A JP 2023580418A JP 2024526237 A5 JP2024526237 A5 JP 2024526237A5
Authority
JP
Japan
Prior art keywords
cells
derived
cell
population
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073396 external-priority patent/WO2023279112A1/en
Publication of JP2024526237A publication Critical patent/JP2024526237A/ja
Publication of JP2024526237A5 publication Critical patent/JP2024526237A5/ja
Pending legal-status Critical Current

Links

JP2023580418A 2021-07-02 2022-07-01 同種異系養子細胞療法のための保護されたエフェクター細胞及びその使用 Pending JP2024526237A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163218204P 2021-07-02 2021-07-02
US63/218,204 2021-07-02
US202163265190P 2021-12-09 2021-12-09
US63/265,190 2021-12-09
US202263341943P 2022-05-13 2022-05-13
US63/341,943 2022-05-13
PCT/US2022/073396 WO2023279112A1 (en) 2021-07-02 2022-07-01 Protected effector cells and use thereof for allogeneic adoptive cell therapies

Publications (2)

Publication Number Publication Date
JP2024526237A JP2024526237A (ja) 2024-07-17
JP2024526237A5 true JP2024526237A5 (cg-RX-API-DMAC7.html) 2025-07-09

Family

ID=84690870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580418A Pending JP2024526237A (ja) 2021-07-02 2022-07-01 同種異系養子細胞療法のための保護されたエフェクター細胞及びその使用

Country Status (9)

Country Link
US (1) US20240307540A1 (cg-RX-API-DMAC7.html)
EP (1) EP4363557A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526237A (cg-RX-API-DMAC7.html)
KR (1) KR20240031361A (cg-RX-API-DMAC7.html)
AU (1) AU2022304599A1 (cg-RX-API-DMAC7.html)
CA (1) CA3223323A1 (cg-RX-API-DMAC7.html)
IL (1) IL309797A (cg-RX-API-DMAC7.html)
MX (1) MX2023015376A (cg-RX-API-DMAC7.html)
WO (1) WO2023279112A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024315647A1 (en) * 2023-08-02 2026-02-12 Fate Therapeutics, Inc. Solid tumor targeting backbone promoting effector cell differentiation and function
WO2025055927A1 (en) * 2023-09-13 2025-03-20 Qihan Hong Kong Limited Immunotherapies using hypoimmunogenic engineered cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
US12036241B2 (en) * 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
AU2019243315A1 (en) * 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
JP2022510207A (ja) * 2018-12-02 2022-01-26 フェイト セラピューティクス,インコーポレイテッド 増強されたiPSC派生エフェクター細胞を使用した免疫療法
AU2020307667A1 (en) * 2019-06-27 2022-01-20 Crispr Therapeutics Ag Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
KR20220035190A (ko) * 2019-07-17 2022-03-21 페이트 세러퓨틱스, 인코포레이티드 면역 효과기 세포 조작 및 이의 용도
US20220378831A1 (en) * 2019-09-25 2022-12-01 Fate Therapeutics, Inc. Multi-targeting effector cells and use thereof
JP7879804B2 (ja) * 2019-12-06 2026-06-24 フェイト セラピューティクス,インコーポレイテッド 小化合物を使用するiPSC由来エフェクター免疫細胞の増強

Similar Documents

Publication Publication Date Title
JP2022541441A5 (cg-RX-API-DMAC7.html)
JP2022550899A5 (cg-RX-API-DMAC7.html)
JP2022548943A5 (cg-RX-API-DMAC7.html)
Xu et al. Natural killer cell-based immunotherapy for acute myeloid leukemia
JP2021505131A5 (cg-RX-API-DMAC7.html)
JP2022510207A5 (cg-RX-API-DMAC7.html)
JP2023505206A5 (cg-RX-API-DMAC7.html)
JP2023530704A5 (cg-RX-API-DMAC7.html)
Maher Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells
JP2023548467A5 (cg-RX-API-DMAC7.html)
JP2023549098A5 (cg-RX-API-DMAC7.html)
CA3107675A1 (en) Improving the efficacy and safety of adoptive cellular therapies
EP3291835B1 (en) Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same
JP2023548829A5 (cg-RX-API-DMAC7.html)
JP2024502157A (ja) 樹状細胞活性化キメラ抗原受容体及びその使用
DK3029137T3 (en) GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF
JP2023545992A5 (cg-RX-API-DMAC7.html)
US12203098B2 (en) Cells having solid tumor targeting backbone and use thereof
KR20210033941A (ko) 개선된 t-세포 요법
KR20250133399A (ko) 유전자 전달 및 합성 및 면역 수용체의 활성을 제어하기 위한 방법 및 조성물
JP2024515920A5 (cg-RX-API-DMAC7.html)
JP2025506515A (ja) 血中のキメラ抗原受容体細胞のブースト
JP2024540237A5 (cg-RX-API-DMAC7.html)
CN118339178A (zh) 包括白细胞介素-9受体信号传导结构域的嵌合抗原受体
WO2025214498A1 (en) Composition and method of cellular immunotherapy